At Toyota we have developed a software program for more security

Roma, 24 ot. (Adnkronos Salute) – The aim is to establish a strategic competitiveness strategy for Italy and for Europe, which will ensure that economic capital and investments are attracted, that a strategy is developed to support the rice starca and guarantee the capacity of the form. It attracts talent from the scientific community of the future. There is a question at the center of the second edition of Forum Incyte, which promotes the Roma and biopharmaceuticals of Incyte Italia, in collaboration with the Formiche and healthcare policy.

When we tried this evening and the current situation for the different parts of the system of Paese and announced a confrontation with a clinic in Italy, there are possibilities for cogliere and the most important confrontations, at a moment of crucial importance for Italy and per l’Europe. The gap in innovation that separates the daily state unit and the Cina is becoming larger and larger in the series of new innovations, is due to biotechnology and is one of the main possibilities to recover terreno. In the midst of the discussion about the importance of the value of capital, the appropriate forms and instruments can be formed that generate the transfer and return of the market, which generate the value of society. If Italiani receives rice and a second premium in Ue (61 Start subsidy ​​in 2024), Italy will scivola already quinto posto se si consideration and allocation of rice vuti come Paese (41).

“The scientific engine of innovation is one of the key players in the quest for self-initiative in the world,” says Chiara Ambrogio, full professor and group leader at the Centro di biotecnologie molecolari (Mbc) of the University of Turin, winner of the Career Development Award In 2018, he was a member of the Summer School selection committee of the Armenian Harvard Foundation, where he had the opportunity to “create innovative education and infrastructure that attracts and treats the ability and prioritizes ensuring the competitiveness of our scientific community” . “A strategic goal of the University Campus Bio-Medico di Roma – with Andrea Rossi, delegate and director general of the Ucbm – is a guarantee of an excellent global education, such as the technique, all the time and all the time The strategy of Vincent is integrated into the formative partnership with the impression of the progressive, national and international countries and the protocol of the international economy with Incyte Italia to appreciate the talent of the laureate in the material field and to be an important bag in his quest for success .

While we deal with innovation and innovation material, the life science, with the biotech in the test, can play a leading role in the world of investing in R&S, in the value of assoluto and in the percentage growth. If you plan to invest in an agricultural business between 2025 and 2030, it will cost 2,000 million euros per 80% dedicated to a rice network. The Life Sciences comparison started with a strategic course in Italy, which has invested solo in the pharmaceutical and biotech sector 2 million euros in 2023 and considered 21% until 5 years ago.

“Oggi the pipeline pharmaceuticals and its vast history – comments on Fabrizio Greco, president of Assobiotec – and about 20 million pharmaceutical companies in the world, about 45% of the origins of biotechnology. Biotechnology follows a Ruolo who has changed the entire geopolitical situation criticizes The future, at the end of public opinion, as the European Union enters into a competitive competitive battle, Ricerca & Sviluppo has invested in the US in 52% of the total global economy by 2023, while Europe has invested solo in 16 years. %. As a surveillance of all Italy, photographs and a Paese leader in the production of pharmaceutical products, 18% of the total Europe is responsible for 6% continental investments in R&S, to compete in the fight against Paese they are more attractive to the invest in esters and combine incentives for the R&S such as simplification, stability and certainty of regulation”.

Secondo Carlo Riccini, Deputy Director General of the Agribusiness: “The innovation in life sciences is fundamental for the salute, sicurezza, crescita, occupation of quality. The pharmaceutical industry is a leader at the global level for R&S and great in Italy for investments in open innovation, +75% in 10 years a partnership has been created with universities and public money, while most of Europe is invested in the future in an important credibility, now that the president of the agricultural industry has paid a good price. I think that politics ensures the attractiveness and competitiveness of intellectual property, so that we have a tendency to quote global investments.”